search
Back to results

Comparison of 10 kHz SCS Combined With CMM to CMM Alone in the Treatment of Neuropathic Limb Pain (SENZA-PDN)

Primary Purpose

Painful Diabetic Neuropathy

Status
Unknown status
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Senza HF10 Therapy
CMM
Sponsored by
Nevro Corp
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Painful Diabetic Neuropathy

Eligibility Criteria

22 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Have been clinically diagnosed with painful diabetic neuropathy (PDN) of the lower limbs.
  2. Average pain intensity of ≥ 5 out of 10 cm on the VAS in the lower extremities at enrollment.
  3. Have stable neurological status.
  4. Be on a stable analgesic regimen.
  5. Be 22 years of age or older at the time of enrollment.
  6. Be an appropriate candidate for the surgical procedures required in this study.
  7. Be capable of subjective evaluation, able to read and understand English-written questionnaires, and able to read, understand and sign the written informed consent in English.
  8. Be willing and capable of giving informed consent.
  9. Be willing and able to comply with study-related requirements, procedures, and scheduled visits.

Exclusion Criteria:

  1. Have a diagnosis of a lower limb mononeuropathy, have had a lower limb amputation, or have large (≥3 cm) and/or gangrenous ulcers of the lower limbs.
  2. Have a BMI ≥ 40.
  3. Currently prescribed a daily opioid dosage > 120 mg morphine equivalents.
  4. Have a medical condition or pain in other area(s), not intended to be treated in this study.
  5. Have a current diagnosis of a progressive neurological disease such a multiple sclerosis, chronic inflammatory demyelinating polyneuropathy, rapidly progressive arachnoiditis, brain or spinal cord tumor, central deafferentation syndrome, Complex Regional Pain Syndrome, acute herniating disc, severe spinal stenosis and brachial plexus injury.
  6. Have a current diagnosis or condition such as a coagulation disorder, bleeding diathesis, platelet dysfunction, low platelet count, severely diminished functional capacity due to underlying cardiac/pulmonary disease, symptomatic uncontrolled hypertension, progressive peripheral vascular disease or uncontrolled diabetes mellitus that presents excess risk for performing the procedure.
  7. Have failed prior SCS, dorsal root ganglion (DRG) stimulation, or peripheral nerve stimulation (PNS) trials for chronic intractable pain.
  8. Have significant spinal stenosis, objective evidence of epidural scarring and/or any signs or symptoms of myelopathy.
  9. Any previous history of surgery on the posterior elements (laminectomy, posterior fusion) resulting in a compromised epidural space.
  10. Be benefitting from an interventional procedure and/or surgery to treat lower limb pain.
  11. Have an existing drug pump and/or another active implantable device such as a pacemaker.
  12. Have a condition currently requiring or likely to require the use of diathermy or MRI that is inconsistent with Senza system guidelines in the Physician's Manual.
  13. Have either a metastatic malignant neoplasm or untreated local malignant neoplasm.
  14. Have a life expectancy of less than one year.
  15. Have a local infection at the anticipated surgical entry site or an active systemic infection.
  16. Be pregnant or plan to become pregnant during the study. Women of childbearing potential who are sexually active must use a reliable form of birth control, be surgically sterile, or be at least 2 years post-menopausal.
  17. Have within 6 months of enrollment a significant untreated addiction to dependency producing medications, alcohol or illicit drugs.
  18. Be concomitantly participating in another clinical study.
  19. Be involved in an injury claim under current litigation.
  20. Be a recipient of Social Security Disability Insurance (SSDI).
  21. Have a pending or approved worker's compensation claim.
  22. Have evidence of an active disruptive psychological or psychiatric disorder or other known condition significant enough to impact perception of pain, compliance with intervention and/or ability to evaluate treatment outcome.

Sites / Locations

  • Coastal Orthopedics
  • Georgia Pain Care
  • Duke University Medical Center
  • Advanced Pain Management

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Other

Arm Label

HF10 therapy plus CMM

CMM Alone

Arm Description

The addition of HF10 (10kHz SCS) therapy to Conventional Medical Management

Conventional Medical Management

Outcomes

Primary Outcome Measures

Composite of Safety and Effectiveness
Difference between treatment groups in responder rates in subjects without a clinically meaningful neurological deficit compared with baseline. Responder is defined as a subject who has at least 50% reduction in lower limb pain from Baseline as measured by a 10 cm Visual Analog Scale (VAS).

Secondary Outcome Measures

Pain Scores of 3 or Less
Difference between the treatment groups in proportion of subjects with a lower limb pain VAS score ≤ 3 cm.
Crossover Rates
Difference between the treatment groups in crossover rates. Subjects who meet pre-specified criteria may elect to crossover to the other treatment arm at 6-month follow-up.
Responder Rates
Difference between the treatment groups in responder rates. Responder is defined as a subject who has at least 50% reduction in lower limb pain from Baseline as measured by a 10 cm Visual Analog Scale (VAS).
Remitter Rates
Difference between the treatment groups in the proportion of remitters (remission is defined as having a lower limb pain VAS score of ≤ 3.0 cm for at least 6 months).
Neurological Assessment
Difference between the treatment groups in the proportion of subjects with overall improvement from baseline in neurological assessment (motor, sensory, reflex).
Neurological Assessment
Difference between the treatment groups in the proportion of subjects with overall improvement from baseline in neurological assessment (motor, sensory, reflex).
Health-related Quality of Life
Difference between the treatment groups in changes in health-related quality of life as assessed by the EuroQol Five Dimensions questionnaire (EQ-5D-5L).
Hemoglobin A1c
Difference between the treatment groups in the average percentage change from baseline in HbA1c levels.

Full Information

First Posted
July 12, 2017
Last Updated
July 17, 2021
Sponsor
Nevro Corp
search

1. Study Identification

Unique Protocol Identification Number
NCT03228420
Brief Title
Comparison of 10 kHz SCS Combined With CMM to CMM Alone in the Treatment of Neuropathic Limb Pain
Acronym
SENZA-PDN
Official Title
A Post-Market, Multicenter, Prospective, Randomized Clinical Trial Comparing 10 kHz Spinal Cord Stimulation (HF10™ Therapy) Combined With Conventional Medical Management to Conventional Medical Management Alone in the Treatment of Chronic, Intractable, Neuropathic Limb Pain
Study Type
Interventional

2. Study Status

Record Verification Date
July 2021
Overall Recruitment Status
Unknown status
Study Start Date
July 20, 2017 (Actual)
Primary Completion Date
May 1, 2020 (Actual)
Study Completion Date
December 1, 2022 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Nevro Corp

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Product Manufactured in and Exported from the U.S.
No

5. Study Description

Brief Summary
This post-market study is being conducted to document comparative safety, clinical effectiveness, and cost-effectiveness of the addition of HF10™ therapy to CMM compared with CMM alone in subjects with chronic, intractable, neuropathic lower limb pain due to diabetic neuropathy (Painful Diabetic Neuropathy or PDN). This study is a multi-center, prospective, randomized comparison of the two treatments.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Painful Diabetic Neuropathy

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
430 (Actual)

8. Arms, Groups, and Interventions

Arm Title
HF10 therapy plus CMM
Arm Type
Active Comparator
Arm Description
The addition of HF10 (10kHz SCS) therapy to Conventional Medical Management
Arm Title
CMM Alone
Arm Type
Other
Arm Description
Conventional Medical Management
Intervention Type
Device
Intervention Name(s)
Senza HF10 Therapy
Intervention Description
Senza 10kHz Spinal Cord Stimulation
Intervention Type
Other
Intervention Name(s)
CMM
Intervention Description
Conventional Medical Management
Primary Outcome Measure Information:
Title
Composite of Safety and Effectiveness
Description
Difference between treatment groups in responder rates in subjects without a clinically meaningful neurological deficit compared with baseline. Responder is defined as a subject who has at least 50% reduction in lower limb pain from Baseline as measured by a 10 cm Visual Analog Scale (VAS).
Time Frame
3 months
Secondary Outcome Measure Information:
Title
Pain Scores of 3 or Less
Description
Difference between the treatment groups in proportion of subjects with a lower limb pain VAS score ≤ 3 cm.
Time Frame
3 months
Title
Crossover Rates
Description
Difference between the treatment groups in crossover rates. Subjects who meet pre-specified criteria may elect to crossover to the other treatment arm at 6-month follow-up.
Time Frame
6 months
Title
Responder Rates
Description
Difference between the treatment groups in responder rates. Responder is defined as a subject who has at least 50% reduction in lower limb pain from Baseline as measured by a 10 cm Visual Analog Scale (VAS).
Time Frame
6 months
Title
Remitter Rates
Description
Difference between the treatment groups in the proportion of remitters (remission is defined as having a lower limb pain VAS score of ≤ 3.0 cm for at least 6 months).
Time Frame
6 months
Title
Neurological Assessment
Description
Difference between the treatment groups in the proportion of subjects with overall improvement from baseline in neurological assessment (motor, sensory, reflex).
Time Frame
3 months
Title
Neurological Assessment
Description
Difference between the treatment groups in the proportion of subjects with overall improvement from baseline in neurological assessment (motor, sensory, reflex).
Time Frame
6 months
Title
Health-related Quality of Life
Description
Difference between the treatment groups in changes in health-related quality of life as assessed by the EuroQol Five Dimensions questionnaire (EQ-5D-5L).
Time Frame
6 months
Title
Hemoglobin A1c
Description
Difference between the treatment groups in the average percentage change from baseline in HbA1c levels.
Time Frame
6 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
22 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Have been clinically diagnosed with painful diabetic neuropathy (PDN) of the lower limbs. Average pain intensity of ≥ 5 out of 10 cm on the VAS in the lower extremities at enrollment. Have stable neurological status. Be on a stable analgesic regimen. Be 22 years of age or older at the time of enrollment. Be an appropriate candidate for the surgical procedures required in this study. Be capable of subjective evaluation, able to read and understand English-written questionnaires, and able to read, understand and sign the written informed consent in English. Be willing and capable of giving informed consent. Be willing and able to comply with study-related requirements, procedures, and scheduled visits. Exclusion Criteria: Have a diagnosis of a lower limb mononeuropathy, have had a lower limb amputation, or have large (≥3 cm) and/or gangrenous ulcers of the lower limbs. Have a BMI ≥ 40. Currently prescribed a daily opioid dosage > 120 mg morphine equivalents. Have a medical condition or pain in other area(s), not intended to be treated in this study. Have a current diagnosis of a progressive neurological disease such a multiple sclerosis, chronic inflammatory demyelinating polyneuropathy, rapidly progressive arachnoiditis, brain or spinal cord tumor, central deafferentation syndrome, Complex Regional Pain Syndrome, acute herniating disc, severe spinal stenosis and brachial plexus injury. Have a current diagnosis or condition such as a coagulation disorder, bleeding diathesis, platelet dysfunction, low platelet count, severely diminished functional capacity due to underlying cardiac/pulmonary disease, symptomatic uncontrolled hypertension, progressive peripheral vascular disease or uncontrolled diabetes mellitus that presents excess risk for performing the procedure. Have failed prior SCS, dorsal root ganglion (DRG) stimulation, or peripheral nerve stimulation (PNS) trials for chronic intractable pain. Have significant spinal stenosis, objective evidence of epidural scarring and/or any signs or symptoms of myelopathy. Any previous history of surgery on the posterior elements (laminectomy, posterior fusion) resulting in a compromised epidural space. Be benefitting from an interventional procedure and/or surgery to treat lower limb pain. Have an existing drug pump and/or another active implantable device such as a pacemaker. Have a condition currently requiring or likely to require the use of diathermy or MRI that is inconsistent with Senza system guidelines in the Physician's Manual. Have either a metastatic malignant neoplasm or untreated local malignant neoplasm. Have a life expectancy of less than one year. Have a local infection at the anticipated surgical entry site or an active systemic infection. Be pregnant or plan to become pregnant during the study. Women of childbearing potential who are sexually active must use a reliable form of birth control, be surgically sterile, or be at least 2 years post-menopausal. Have within 6 months of enrollment a significant untreated addiction to dependency producing medications, alcohol or illicit drugs. Be concomitantly participating in another clinical study. Be involved in an injury claim under current litigation. Be a recipient of Social Security Disability Insurance (SSDI). Have a pending or approved worker's compensation claim. Have evidence of an active disruptive psychological or psychiatric disorder or other known condition significant enough to impact perception of pain, compliance with intervention and/or ability to evaluate treatment outcome.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
David Caraway, MD
Organizational Affiliation
Nevro Corp
Official's Role
Study Director
Facility Information:
Facility Name
Coastal Orthopedics
City
Bradenton
State/Province
Florida
ZIP/Postal Code
34209
Country
United States
Facility Name
Georgia Pain Care
City
Stockbridge
State/Province
Georgia
ZIP/Postal Code
30281
Country
United States
Facility Name
Duke University Medical Center
City
Durham
State/Province
North Carolina
ZIP/Postal Code
27710
Country
United States
Facility Name
Advanced Pain Management
City
Greenfield
State/Province
Wisconsin
ZIP/Postal Code
53221
Country
United States

12. IPD Sharing Statement

Citations:
PubMed Identifier
35814185
Citation
Petersen EA, Stauss TG, Scowcroft JA, Brooks ES, White JL, Sills SM, Amirdelfan K, Guirguis MN, Xu J, Yu C, Nairizi A, Patterson DG, Tsoulfas KC, Creamer MJ, Galan V, Bundschu RH, Mehta ND, Sayed D, Lad SP, DiBenedetto DJ, Sethi KA, Goree JH, Bennett MT, Harrison NJ, Israel AF, Chang P, Wu PW, Argoff CE, Nasr CE, Taylor RS, Caraway DL, Mekhail NA. High-Frequency 10-kHz Spinal Cord Stimulation Improves Health-Related Quality of Life in Patients With Refractory Painful Diabetic Neuropathy: 12-Month Results From a Randomized Controlled Trial. Mayo Clin Proc Innov Qual Outcomes. 2022 Jul 1;6(4):347-360. doi: 10.1016/j.mayocpiqo.2022.05.003. eCollection 2022 Aug.
Results Reference
derived
PubMed Identifier
34854473
Citation
O'Connell NE, Ferraro MC, Gibson W, Rice AS, Vase L, Coyle D, Eccleston C. Implanted spinal neuromodulation interventions for chronic pain in adults. Cochrane Database Syst Rev. 2021 Dec 2;12(12):CD013756. doi: 10.1002/14651858.CD013756.pub2.
Results Reference
derived
PubMed Identifier
34844993
Citation
Petersen EA, Stauss TG, Scowcroft JA, Brooks ES, White JL, Sills SM, Amirdelfan K, Guirguis MN, Xu J, Yu C, Nairizi A, Patterson DG, Tsoulfas KC, Creamer MJ, Galan V, Bundschu RH, Mehta ND, Sayed D, Lad SP, DiBenedetto DJ, Sethi KA, Goree JH, Bennett MT, Harrison NJ, Israel AF, Chang P, Wu PW, Argoff CE, Nasr CE, Taylor RS, Caraway DL, Mekhail NA. Durability of High-Frequency 10-kHz Spinal Cord Stimulation for Patients With Painful Diabetic Neuropathy Refractory to Conventional Treatments: 12-Month Results From a Randomized Controlled Trial. Diabetes Care. 2022 Jan 1;45(1):e3-e6. doi: 10.2337/dc21-1813. No abstract available.
Results Reference
derived
PubMed Identifier
33818600
Citation
Petersen EA, Stauss TG, Scowcroft JA, Brooks ES, White JL, Sills SM, Amirdelfan K, Guirguis MN, Xu J, Yu C, Nairizi A, Patterson DG, Tsoulfas KC, Creamer MJ, Galan V, Bundschu RH, Paul CA, Mehta ND, Choi H, Sayed D, Lad SP, DiBenedetto DJ, Sethi KA, Goree JH, Bennett MT, Harrison NJ, Israel AF, Chang P, Wu PW, Gekht G, Argoff CE, Nasr CE, Taylor RS, Subbaroyan J, Gliner BE, Caraway DL, Mekhail NA. Effect of High-frequency (10-kHz) Spinal Cord Stimulation in Patients With Painful Diabetic Neuropathy: A Randomized Clinical Trial. JAMA Neurol. 2021 Jun 1;78(6):687-698. doi: 10.1001/jamaneurol.2021.0538.
Results Reference
derived
PubMed Identifier
31941531
Citation
Mekhail NA, Argoff CE, Taylor RS, Nasr C, Caraway DL, Gliner BE, Subbaroyan J, Brooks ES. High-frequency spinal cord stimulation at 10 kHz for the treatment of painful diabetic neuropathy: design of a multicenter, randomized controlled trial (SENZA-PDN). Trials. 2020 Jan 15;21(1):87. doi: 10.1186/s13063-019-4007-y.
Results Reference
derived

Learn more about this trial

Comparison of 10 kHz SCS Combined With CMM to CMM Alone in the Treatment of Neuropathic Limb Pain

We'll reach out to this number within 24 hrs